Research programme: IRAK4 scaffolding inhibitors - Odyssey Therapeutics
Alternative Names: IRAK4 scaffolding inhibitorsLatest Information Update: 01 Jan 2024
At a glance
- Originator Odyssey Therapeutics
- Class Anti-inflammatories
- Mechanism of Action IRAK4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 10 Nov 2023 Preclinical trials in Inflammation in USA (unspecified route), prior to November 2023
- 10 Nov 2023 Pharmacodynamics data from preclinical studies in Inflammation presented at the American College of Rheumatology Convergence (ACR-ARP-2023)
- 07 Dec 2021 Early research in Inflammation in USA (unspecified route)